Comparison of in vitro and in vivo α/β ratios for prostate cancer

David J. Carlson, Robert D. Stewart, X. Allen Li, Kristofer Jennings, Jian Z. Wang, M. Guerrero

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Parallel in vitro and in vivo studies provide insight into the relationship between clinical response and intrinsic cellular radiosensitivity and may aid in the development of predictive assays. Compilations of radiosensitivity parameters from in vitro experiments can also be used to examine the potential effectiveness of alternative or new treatment plan designs until enough clinical data become available to directly estimate the requisite radiosensitivity parameters. In this work, survival data for six prostate cancer cell lines (ten datasets total) have been extracted from the literature and re-analysed using the linear-quadratic (LQ) survival model. The paired bootstrap technique for regression is used to compute 95% confidence intervals for the estimated radiosensitivity parameters. LQ radiosensitivity parameters derived from the in vitro data are then compared to radiosensitivity parameters derived from clinical data for prostate cancer. Estimates of α range from 0.09 to 0.35 Gy-1 (all cell lines), and the α /β ratio ranges from 1.09 to 6.29 Gy (all cell lines). Point estimates of the repair half-time (PPC-1, TSU-Pr1, PC-3 and DU-145 cell lines) range from 5.7 to 8.9 h (95% confidence interval from 0.26 h to 10.7 h). Differences in the radiosensitivity parameters determined from the data reported by different laboratories are as large as or larger than the differences in radiosensitivity parameters observed among the various prostate cell lines. The reported studies demonstrate that even seemingly small corrections for dose rate effects, such as those expected in high dose rate (HDR) experiments, can sometimes have a significant impact on estimates of α and α/β. By neglecting dose rate effects in the analysis of HDR experiments, estimates of the α/β ratio may be too high by factors as large as 1.3 to 6.2. The half-time for repair derived from the in vitro experiments appears significantly larger (slower repair rate) than estimates derived from the clinical data. However, the prostate radiosensitivity parameters α and α/β may be approximately the same in vitro and in vivo. Most of the in vitro data are consistent with an α/β ratio for prostate cancer less than 3 or 4 Gy.

Original languageEnglish (US)
Pages (from-to)4477-4491
Number of pages15
JournalPhysics in Medicine and Biology
Volume49
Issue number19
DOIs
StatePublished - Oct 7 2004
Externally publishedYes

Fingerprint

Radiation Tolerance
radiation tolerance
Prostatic Neoplasms
cancer
Cells
cultured cells
Repair
Cell Line
estimates
Experiments
dosage
Prostate
confidence
Assays
Confidence Intervals
intervals
In Vitro Techniques
regression analysis

ASJC Scopus subject areas

  • Biomedical Engineering
  • Physics and Astronomy (miscellaneous)
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Comparison of in vitro and in vivo α/β ratios for prostate cancer. / Carlson, David J.; Stewart, Robert D.; Li, X. Allen; Jennings, Kristofer; Wang, Jian Z.; Guerrero, M.

In: Physics in Medicine and Biology, Vol. 49, No. 19, 07.10.2004, p. 4477-4491.

Research output: Contribution to journalArticle

Carlson, David J. ; Stewart, Robert D. ; Li, X. Allen ; Jennings, Kristofer ; Wang, Jian Z. ; Guerrero, M. / Comparison of in vitro and in vivo α/β ratios for prostate cancer. In: Physics in Medicine and Biology. 2004 ; Vol. 49, No. 19. pp. 4477-4491.
@article{476b9926d3564dc0bb4cc580299a9dcb,
title = "Comparison of in vitro and in vivo α/β ratios for prostate cancer",
abstract = "Parallel in vitro and in vivo studies provide insight into the relationship between clinical response and intrinsic cellular radiosensitivity and may aid in the development of predictive assays. Compilations of radiosensitivity parameters from in vitro experiments can also be used to examine the potential effectiveness of alternative or new treatment plan designs until enough clinical data become available to directly estimate the requisite radiosensitivity parameters. In this work, survival data for six prostate cancer cell lines (ten datasets total) have been extracted from the literature and re-analysed using the linear-quadratic (LQ) survival model. The paired bootstrap technique for regression is used to compute 95{\%} confidence intervals for the estimated radiosensitivity parameters. LQ radiosensitivity parameters derived from the in vitro data are then compared to radiosensitivity parameters derived from clinical data for prostate cancer. Estimates of α range from 0.09 to 0.35 Gy-1 (all cell lines), and the α /β ratio ranges from 1.09 to 6.29 Gy (all cell lines). Point estimates of the repair half-time (PPC-1, TSU-Pr1, PC-3 and DU-145 cell lines) range from 5.7 to 8.9 h (95{\%} confidence interval from 0.26 h to 10.7 h). Differences in the radiosensitivity parameters determined from the data reported by different laboratories are as large as or larger than the differences in radiosensitivity parameters observed among the various prostate cell lines. The reported studies demonstrate that even seemingly small corrections for dose rate effects, such as those expected in high dose rate (HDR) experiments, can sometimes have a significant impact on estimates of α and α/β. By neglecting dose rate effects in the analysis of HDR experiments, estimates of the α/β ratio may be too high by factors as large as 1.3 to 6.2. The half-time for repair derived from the in vitro experiments appears significantly larger (slower repair rate) than estimates derived from the clinical data. However, the prostate radiosensitivity parameters α and α/β may be approximately the same in vitro and in vivo. Most of the in vitro data are consistent with an α/β ratio for prostate cancer less than 3 or 4 Gy.",
author = "Carlson, {David J.} and Stewart, {Robert D.} and Li, {X. Allen} and Kristofer Jennings and Wang, {Jian Z.} and M. Guerrero",
year = "2004",
month = "10",
day = "7",
doi = "10.1088/0031-9155/49/19/003",
language = "English (US)",
volume = "49",
pages = "4477--4491",
journal = "Physics in Medicine and Biology",
issn = "0031-9155",
publisher = "IOP Publishing Ltd.",
number = "19",

}

TY - JOUR

T1 - Comparison of in vitro and in vivo α/β ratios for prostate cancer

AU - Carlson, David J.

AU - Stewart, Robert D.

AU - Li, X. Allen

AU - Jennings, Kristofer

AU - Wang, Jian Z.

AU - Guerrero, M.

PY - 2004/10/7

Y1 - 2004/10/7

N2 - Parallel in vitro and in vivo studies provide insight into the relationship between clinical response and intrinsic cellular radiosensitivity and may aid in the development of predictive assays. Compilations of radiosensitivity parameters from in vitro experiments can also be used to examine the potential effectiveness of alternative or new treatment plan designs until enough clinical data become available to directly estimate the requisite radiosensitivity parameters. In this work, survival data for six prostate cancer cell lines (ten datasets total) have been extracted from the literature and re-analysed using the linear-quadratic (LQ) survival model. The paired bootstrap technique for regression is used to compute 95% confidence intervals for the estimated radiosensitivity parameters. LQ radiosensitivity parameters derived from the in vitro data are then compared to radiosensitivity parameters derived from clinical data for prostate cancer. Estimates of α range from 0.09 to 0.35 Gy-1 (all cell lines), and the α /β ratio ranges from 1.09 to 6.29 Gy (all cell lines). Point estimates of the repair half-time (PPC-1, TSU-Pr1, PC-3 and DU-145 cell lines) range from 5.7 to 8.9 h (95% confidence interval from 0.26 h to 10.7 h). Differences in the radiosensitivity parameters determined from the data reported by different laboratories are as large as or larger than the differences in radiosensitivity parameters observed among the various prostate cell lines. The reported studies demonstrate that even seemingly small corrections for dose rate effects, such as those expected in high dose rate (HDR) experiments, can sometimes have a significant impact on estimates of α and α/β. By neglecting dose rate effects in the analysis of HDR experiments, estimates of the α/β ratio may be too high by factors as large as 1.3 to 6.2. The half-time for repair derived from the in vitro experiments appears significantly larger (slower repair rate) than estimates derived from the clinical data. However, the prostate radiosensitivity parameters α and α/β may be approximately the same in vitro and in vivo. Most of the in vitro data are consistent with an α/β ratio for prostate cancer less than 3 or 4 Gy.

AB - Parallel in vitro and in vivo studies provide insight into the relationship between clinical response and intrinsic cellular radiosensitivity and may aid in the development of predictive assays. Compilations of radiosensitivity parameters from in vitro experiments can also be used to examine the potential effectiveness of alternative or new treatment plan designs until enough clinical data become available to directly estimate the requisite radiosensitivity parameters. In this work, survival data for six prostate cancer cell lines (ten datasets total) have been extracted from the literature and re-analysed using the linear-quadratic (LQ) survival model. The paired bootstrap technique for regression is used to compute 95% confidence intervals for the estimated radiosensitivity parameters. LQ radiosensitivity parameters derived from the in vitro data are then compared to radiosensitivity parameters derived from clinical data for prostate cancer. Estimates of α range from 0.09 to 0.35 Gy-1 (all cell lines), and the α /β ratio ranges from 1.09 to 6.29 Gy (all cell lines). Point estimates of the repair half-time (PPC-1, TSU-Pr1, PC-3 and DU-145 cell lines) range from 5.7 to 8.9 h (95% confidence interval from 0.26 h to 10.7 h). Differences in the radiosensitivity parameters determined from the data reported by different laboratories are as large as or larger than the differences in radiosensitivity parameters observed among the various prostate cell lines. The reported studies demonstrate that even seemingly small corrections for dose rate effects, such as those expected in high dose rate (HDR) experiments, can sometimes have a significant impact on estimates of α and α/β. By neglecting dose rate effects in the analysis of HDR experiments, estimates of the α/β ratio may be too high by factors as large as 1.3 to 6.2. The half-time for repair derived from the in vitro experiments appears significantly larger (slower repair rate) than estimates derived from the clinical data. However, the prostate radiosensitivity parameters α and α/β may be approximately the same in vitro and in vivo. Most of the in vitro data are consistent with an α/β ratio for prostate cancer less than 3 or 4 Gy.

UR - http://www.scopus.com/inward/record.url?scp=5744247185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5744247185&partnerID=8YFLogxK

U2 - 10.1088/0031-9155/49/19/003

DO - 10.1088/0031-9155/49/19/003

M3 - Article

VL - 49

SP - 4477

EP - 4491

JO - Physics in Medicine and Biology

JF - Physics in Medicine and Biology

SN - 0031-9155

IS - 19

ER -